



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/19, 38/20	A1	(11) International Publication Number: WO 97/16202 (43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/AU96/00676 (22) International Filing Date: 25 October 1996 (25.10.96) (30) Priority Data: PN 6242 27 October 1995 (27.10.95) AU PN 6243 27 October 1995 (27.10.95) AU PN 8966 27 March 1996 (27.03.96) AU PO 0364 7 June 1996 (07.06.96) AU (71) Applicant (for all designated States except US): AMRAD OPERATIONS PTY. LTD. [AU/AU]; 17-27 Cotham Road, Kew, VIC 3101 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): DOUGLAS, Andrea, Margaret [AU/AU]; 45 Catherine Road, East Bentleigh, VIC 3165 (AU). BEGLEY, Colin, Glenn [AU/AU]; 3 Era Court, Donvale, VIC 3111 (AU). (74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER		
(57) Abstract <p>The present invention relates generally to a method for the treatment or prophylaxis of animals including humans suffering from or predisposed to breast cancer or other related cancers which comprises the use of cytokines and/or functionally active derivatives, hybrids and/or analogs thereof and to pharmaceutical compositions comprising same as therapeutic agents. In particular, but not exclusively, the present invention is directed to the use of cytokines which are ligands of members of the haemopoietin receptor super family or their derivatives, hybrids or analogs as therapeutic agents. The present application also contemplates breast cancer therapies and methods of suppressing growth of normal breast cells or breast cancer cells by the use of one or more cytokines optionally in combination with other therapeutic agents as well as the use of agonists or antagonists of cytokine activity. Particularly preferred are oncostatin M (OSM) and leukaemia inhibitory factor (LIF).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LU	Luxembourg	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER

The present invention relates generally to a method for the treatment or prophylaxis of
5 animals including humans suffering from or predisposed to breast cancer or other related
cancers which comprises the use of cytokines and/or functionally active derivatives, hybrids
and/or analogs thereof and to pharmaceutical compositions comprising same as therapeutic
agents. In particular, but not exclusively, the present invention is directed to the use of
10 cytokines which are ligands of members of the haemopoietin receptor super family or their
derivatives, hybrids or analogues as therapeutic agents. The present invention also
contemplates breast cancer therapies and methods of suppressing growth of normal breast cells
or breast cancer cells by the use of one or more cytokines optionally in combination with
other therapeutic agents as well as the use of agonists or antagonists of cytokine activity.

15 Bibliographic details of the publications numerically referred to in this specification are
collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the
nucleotide and amino acid sequences referred to in the specification are defined following the
bibliography.

20 Throughout this specification and the claims which follow, unless the context requires
otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be
understood to imply the inclusion of a stated integer or group of integers but not the exclusion
of any other integer or group of integers.

25 Breast cancer is the most common malignancy of females in Western cultures and affects 1
in 13 women in Australia. The risk of death is related to a number of prognostic factors, the
most powerful being whether the axillary lymph nodes are involved. The relapse rate at 10
years has been found to be as high as 85% for women with Stage II disease who display
involvement of four or more axillary lymph nodes (Antman, 1992). In premenopausal
30 patients with more than 10 involved nodes given standard dose adjuvant chemotherapy

- 2 -

cyclophosphamide (C) methotrexate (M) 5 fluoviracil (F) prednisolone (P), greater than 70% have disease recurrence within 5 years of diagnosis. When estrogen receptor (ER) status is included as a prognostic indicator, those patients who have an ER negative tumor with 4 or more nodes involved have risk of recurrence and death which approaches that for patients
5 with 10 or more positive lymph nodes.

In patients with a large primary tumor (eg > 5 cm) and positive nodes (Stage III disease) the 5-year relapse rate is between 65% and 79% (Nemoto *et al.*, 1980; Valagussa *et al.*, 1978; Fisher *et al.*, 1969). In Halsted's original series only 2 of 44 (5%) women with
10 supraclavicular node involvement were free of cancer at 5 years (Halsted, 1907). In women with either fixed axillary nodes, axillary nodes more than 2.5 cm in diameter, tumor fixed to the chest wall or skin ulceration, 5-year disease free survival ranges from only 5% to 38% (Haagensen, 1986). The addition of either CMF chemotherapy or anthracycline-containing chemotherapy to local therapy (surgery +/- radiation to the breast) of stage III breast cancer
15 appears to improve 5-year relapse free survival from 26% to 40% (Balawadger, 1983). Stage IV breast cancer (metastatic disease) is invariably fatal. Thus, this is a disease with a poor outlook and for which new therapeutic strategies are required.

Chemotherapy is currently the mainstay of systemic therapy for breast cancer. Both
20 retrospective (Bonadonna *et al.*, 1981; Hryniuk and Levine, 1986; Hryniuk and Bush, 1984) and prospective (Jones *et al.*, 1987; Focan *et al.*, 1993; Carmo-Pereira *et al.*, 1987; Tannock *et al.*, 1988; Neri *et al.*, 1993; Wood *et al.*, 1994) data demonstrate a dose-response relationship for cytotoxic drugs in breast cancer. On the whole, these clinical studies show that any significant reduction of chemotherapy below a certain critical dose results in a
25 compromise of response rate or shortening of survival. What is not clear is whether the *in vivo* dose-response curve in breast cancer is linear, so that ever increasing doses of cytotoxic agents result in a greater chance of response, or whether a plateau is reached, above which only greater toxicity is observed. A hint is given that the former might apply by the activity reported in studies of growth factor supported, dose-intensive regimens (Bronchud *et al.*,
30 1989; Ardizzoni *et al.*, 1994; Lalisang *et al.*, 1994; Hoekman *et al.*, 1991; Ferguson *et al.*,

- 3 -

1993; Scinto *et al.*, 1995; Piccart *et al.*, 1995) and high-dose chemotherapy with autologous progenitor cell rescue in patients with metastatic breast cancer (Eddy, 1992). These single arm studies produced response rates of 60% to 100% which compares favourably to the 25% to 50% response rates obtained using conventional dose chemotherapy (Jain *et al.*, 1985; 5 Rozenzweig *et al.*, 1984; Van Oosterrom, 1987; Marchner, 1994).

While high-dose chemotherapy in metastatic breast cancer produces impressive response rates, it does not appear to have impacted on survival (Eddy, 1992). However, it might be expected to be more affective if given to patients with early stage breast cancer and features that 10 suggest a likelihood of recurrence. The use of this approach in high-risk stage II and III breast cancer has produced promising initial results. Peters *et al.* (1993) delivered 4 cycles of standard-dose chemotherapy followed by high-dose cyclophosphamide, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and cisplatin to 85 patients with high-risk (> 10 involved axillary lymph nodes) stage II and III breast cancer. At a median follow-up of 2.5 years, the 15 relapse-free survival was 72% and overall survival 82% (Peters *et al.*, 1993). However, this regimen was associated with a 12% treatment-related mortality rate and a high incidence of chronic pulmonary drug toxicity (Todd *et al.*, 1993). Gianni *et al.* (1992) gave 48 patients with > 10 involved axillary nodes growth factor supported high-dose sequential chemotherapy. This regimen included cyclophosphamide, vincristine and methotrexate, 20 cisplatin then melphalan. At a median follow-up of 21 months, relapse-free and overall survival was 93% (Gianni *et al.*, 1992).

The present inventors recently conducted a feasibility study of three cycles of high-dose epirubicin (200mg/m₂) and cyclophosphamide (4 gm/m₂) with peripheral blood progenitor 25 support in women with high risk breast cancer (Basser *et al.*, 1995). Myelosuppression and acute-non-haematological toxicities were marked, but reversible. Given that repeated use of anthracyclines is limited by a dose-dependent, irreversible cardiomyopathy, cardiac function of patients was monitored closely. The left ventricular ejection fraction fell by 15% from baseline in only 4 of 30 patients (13%) when measured at the completion of the third cycle 30 of chemotherapy. No patients at any stage developed symptoms or signs of congestive heart

failure.

Therefore, although chemotherapy is efficacious in the treatment of breast cancer, it is associated with significant toxicities. These toxicities justify the development of new approaches in this disease and have provided the impetus for further research into such new approaches.

Breast cancer has been recognised as a hormone-responsive tumor for nearly a century. The recognition that growth stimulation occurs following the interaction of estrogen with its receptor led to the development of competitively binding anti-estrogens capable of inhibiting breast cancer growth (Li *et al.*, 1992). In addition the presence of estrogen receptors in breast tumors predicts both patient prognosis, and response to hormonal therapy. Moreover treatment with anti-estrogens improves survival of these patients (Osborne *et al.*, 1991; Early Breast Trial Collaborative Group, 1992). More recently, the focus has moved to the possible role of additional growth factors and their cell surface receptors in development and progression of breast cancer and the possibility these pathways might serve as potential targets for therapy.

The *in-vitro* growth of breast cells requires exogenous serum-derived factors for optimal growth. Isolation of protein fractions responsible for this activity resulted in the recognition of several families of growth factors, including epidermal growth factor (EGF), transforming growth factor (TGF), fibroblast growth factor (FGF), insulin and insulin-like growth factors (IGF's), that are important in the growth of these cells. Likewise surface receptors for these growth factors have been identified on breast cells and are found with variable frequency in primary human breast tumor samples (Dickson and Lippmann, 1992; Kacinski *et al.*, 1991; Harris, 1994; Chrysagekos and Dickson, 1994).

A number of "haemopoietic" growth-factors have been characterized that display diverse functions on many different tissues. In some cases, these growth-factors can even display conflicting actions on different tissues. Thus, for example, Leukemia Inhibitory Factor (LIF)

- 5 -

was named because of its ability to induce terminal differentiation in murine M1 leukemia cells. Paradoxically, however, LIF acts to inhibit differentiation on embryonic stem (ES) cells. Moreover, LIF is also active on many cell types including neurones, hepatocytes, osteoblasts, adipocytes and megakaryocytes. These activities of LIF are mediated *via* specific
5 cell-surface receptors that are present on all these tissues (Hilton *et al.*, 1991). A number of other molecules also display a broad-range of activities. These pleiotropic molecules include cytokines such as interleukin-6 (IL-6), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and interleukin-11 (IL-11).

10 In accordance with the present invention, it is proposed that certain cytokines are effective in treating breast cancer.

Accordingly, one embodiment of the present invention contemplates a method for the treatment or prophylaxis of breast cancer in an animal, which method comprises administering
15 to said animal an effective amount of one or more cytokines or functional derivatives or agonists of said one or more cytokines for a time and under conditions sufficient to ameliorate the effects of or to delay onset of said cancer.

Another embodiment of the present invention provides a method for suppressing growth,
20 proliferation or enhancing differentiation of normal breast cells or breast cell carcinomas from animals or immortalised animal breast cell lines by contacting said cells with an effective amount of one or more cytokines or functional derivatives or agonists of one or more cytokines for a time and under conditions sufficient to suppress growth, proliferation or enhancing differentiation of said cells.

25

In a particularly preferred embodiment the present invention contemplates a method of treating or prophylaxis of breast cancer in an animal including a human which method comprises administering to said animal an effective amount of a cytokine selected from OSM, LIF, IL-6, IL-11 and EGF and other members of the EGF family, or functional derivatives
30 or agonists thereof optionally in association with one or more other cytokines or other

therapeutic agents.

Another embodiment of the present invention contemplates a therapeutic composition for the treatment of animals including humans suffering from breast cancer or having a predisposition
5 to develop breast cancer which comprises one or more cytokines or functional derivatives or agonists thereof optionally in association with other therapeutic agents and also in association with one or more pharmaceutically acceptable carriers and/or diluents.

Administration of the active components of the present invention is for a time and under
10 conditions sufficient for said components to exhibit the requisite effect. The term "breast cancer" is used in its broadest sense and includes all forms of breast cancer including but not limited to metastatic breast cancer and early breast cancer. It also includes other cancers epidemiologically related to breast cancer.

15 By the term "animal" it is to be understood that the methods of treatment of the present invention are applicable to the treatment of breast cancer in all mammals and in particular humans as well as in livestock animals (e.g. sheep, cows, pigs, goats, horses, donkeys), laboratory test animals (e.g. mice, rats, guinea pigs, hamsters, rabbits), domestic companion animals (e.g. dogs, cats) and captive wild or tamed animals (e.g. monkeys, foxes, kangaroos,
20 dingoes).

Preferably, the cytokine is a recombinant cytokine of human, murine, livestock animal, companion animal, laboratory test animal or captive wild animal origin. More preferably however, the cytokine is of human origin. The present invention extends to all cytokines
25 which bind to surface receptors of breast cells whether they be normal breast cells, breast cell carcinomas or immortalised breast cell lines of human or animal origins, and which exhibit an activity on cell growth, proliferation or differentiation. In particular, the cytokines of the present invention include oncostatin M (OSM), interleukin-6 (IL-6), interleukin-11 (IL-11), leukemia inhibitory factor (LIF) and EGF and other members of the EGF family. Most
30 preferably, the cytokine of the present invention is OSM of either human or murine origin,

but preferably of human origin. In this regard, homologous or heterologous treatments are contemplated by the present invention. A homologous treatment employs a cytokine from one animal species in the treatment of an animal from the same species (e.g. human OSM in humans). Heterologous treatment employs a cytokine from one animal species in the
5 treatment of an animal of a different species (e.g. murine OSM in humans).

The term "derivatives" extends to functionally active parts, mutants, fragments and analogues of cytokines which exhibit the desired activity herein described.

10 The terms "agonists" and "antagonists" are envisaged compounds which may or may not be cytokines but which facilitate cytokine interaction with its receptors on breast cells or breast cancer cells to elicit an activity, preferably an enhanced or diminished activity depending on whether it is an agonist or antagonist, respectively. One example of an antagonist of a cytokine is use of antisense oligonucleotide sequences. Useful oligonucleotides are those
15 which have a nucleotide sequence complementary to at least a portion of the protein coding or "sense" sequence which encodes the particular cytokine concerned can be utilised. These anti-sense nucleotides can be used to effect the specific inhibition of gene expression (Markus-Sekura, 1988). The antisense approach can cause inhibition of gene expression apparently by forming an anti parallel duplex by complementary base pairing between the antisense
20 construct and the targeted mRNA, presumably resulting in hybridisation arrest of translation.

There have been several reports of antisense effects on cytokine-responsive cells, such as IL- β -responsive lymphokine-activated cells (Fujiwara and Grimm, 1992), TNF- α -responsive differentiating macrophages (Witsell and Schook, 1992), M-CSF-responsive HL-60 cells (Wu
25 *et al*, 1990) and IL-6-responsive cells (Levy *et al*, 1991). These studies have demonstrated the critical role of these genes in the growth of different cell types.

The present invention extends to analogues of cytokines and their use in the treatment or prophylaxis of breast cancer. Analogues of cytokines contemplated herein include, but are not
30 limited to, modification to side chains, incorporating of unnatural amino acids and/or their

- 8 -

derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.

- 5 Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic
10 anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

15

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic
20 acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

25

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

30

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbonylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 1.

10

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(\text{CH}_2)_n$ spacer groups with $n=1$ to $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α -methylamino acids, introduction of double bonds between C_α and C_β atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

20

These types of modifications may be important to stabilise the cytokines if administered to an individual or for use as a diagnostic reagent.

25

- 10 -

TABLE 1

Non-conventional amino acid	Code	Non-conventional amino acid	Code
5			
α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
α -amino- α -methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
10 carboxylate		L-N-methylaspartic acid	Nmasp
aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
aminonorbornyl-	Norb	L-N-methylglutamine	Nmgln
carboxylate		L-N-methylglutamic acid	Nmglu
cyclohexylalanine		Chexa L-N-methylhistidine	Nmhis
15 cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
D-alanine	Dal	L-N-methylleucine	Nmleu
D-arginine	Darg	L-N-methyllysine	Nmlys
D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
20 D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
D-isoleucine	Dile	L-N-methylproline	Nmpro
D-leucine	Dleu	L-N-methylserine	Nmser
25 D-lysine	Dlys	L-N-methylthreonine	Nmthr
D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
D-phenylalanine	Dphe	L-N-methylvaline	Nmval
D-proline	Dpro	L-N-methylethylglycine	Nmetg
30 D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug

	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgabu
5	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
10	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
15	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
20	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
25	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
30	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr

- 12 -

	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
5	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
10	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- <i>n</i> -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
15	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
20	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
25	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
30	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe

- 13 -

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

5

The cytokines may optionally be administered together with one or more other therapeutic agents. These other agents contemplated by the present invention are agents such as chemotherapeutic and hormonal agents which are well known in the art. Examples of some
 10 chemotherapeutic agents are cyclophosphamide, vincristine and methotrexate, cisplatin, melphalan and an example of a common hormonal type agent is tamoxifen. This list of other therapeutic agents is by no means exhaustive. Other useful molecules contemplated herein include taxol (and related molecules such as taxitene) and adriamycin. Such combination therapy may prove effective in treating metastatic breast cancer or in treatment
 15 of early breast cancer in particular.

It is contemplated by the invention that when one or more cytokines are administered in combination with other agents that the administration is done simultaneously or sequentially. Simultaneous administration occurs when the cytokine is co-administered with the other
 20 therapeutic agent. Sequential therapy includes a time difference between administration of the various molecules which may be in the order of seconds, minutes, hours, days, weeks or months depending upon the severity of the patient's condition, the type of mammal being treated and the effectiveness of the overall treatment.

It is also within the scope of the invention to administer a combination of different cytokines. Preferably, the combination comprises a haemopoietin receptor cytokine with another cytokine of the same family or comprises a haemopoietic receptor cytokine and a cytokine from another family. Preferably, the combination comprises OSM and at least one
 25 other cytokine. Even more preferably, the combination comprises OSM together with one
 30 or more of IL-6, IL-11, LIF and/or EGF or another member of the EGF family. For

- 14 -

example, administration of OSM and IL-11 or OSM and LIF or OSM and IL-6 or OSM and EGF or OSM together with LIF, two or more of IL-6, IL-11 and EGF is clearly contemplated by the present invention.

5 The amount of cytokine administered is to be determined on a case by case basis taking into account the condition of the patient, species, weight, age, other concurrent treatments and other factors which would be apparent to a physician. As an example it is envisaged that an amount of from about 0.5 micrograms to about 2 milligrams of cytokine per kilogram of body weight per day may be administered. Naturally, dosage regimes may be adjusted to
10 provide the optimum prophylactic or therapeutic response. For example, several divided dosages may be administered daily or the dose may be proportionally reduced as indicated by the particular therapeutic situation. Furthermore, lower amounts may be given but more frequently such as 0.1 to 10 μ g per kilogram of body weight per day. Alternatively, larger amounts may be given but less frequently such as from 1 milligram to about 25 milligrams
15 per kilogram of body weight per day.

A decided practical advantage is that the active compound may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneously, intranasal, intradermal or suppository routes. The active compound may
20 also be administered locally such as directly into tissue or *via* a slow release formulation. Depending upon the route of administration, the active ingredients may be required to be coated in a material to protect the ingredients from action of enzymes, acids and other natural conditons which may inactivate the ingredients. In order to administer cytokines by other than parenteral administration, they may be coated by or administered with, a material
25 to prevent inactivation. For example, cytokines or in particular OSM, may be administered in an adjuvant formulation or co-administered with enzyme inhibitors or in liposomes.

Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether. Enzyme inhibitors include
30 pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes

include water-in-oil-in-water cytokine emulsions as well as conventional liposomes.

Cytokines may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under
5 ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of
10 sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria or fungi. The carrier can be a coolant of dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol,
15 and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and anti fungal agents, for example, parabens, chlorobutanol, phenol,
20 sorbic acid, thiomerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

25 Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions are prepared incorporating the various sterilised active ingredient(s) into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated
30 above. In the case of sterile powders for the preparation of sterile injectable solutions, the

- 16 -

preferred methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile filtered solution thereof.

- 5 When the active ingredients are suitably protected as described above, the composition may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatine capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the
- 10 form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspension, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% on weight of active compound. The percentage of the compositions and preparations may of course be varied and may conventionally be between about 5 to about 80% of the weight of the unit. The amount of active compound(s) in the pharmaceutical compositions is such that
- 15 a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared, so that an oral dosage unit form contains between about 0.5 nanogram and 320 milligram of active compound.

The tablets, troches, pills capsules and the like may also contain the following: a binder such

20 as gum gragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate, a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above

25 type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any

30 dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts

employed. In addition, the active compound may be incorporated into sustained release preparations and formulations.

As used herein "pharmaceutically acceptable carriers and/or diluents" include any and all
5 solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents
isotonic and absorption delaying agents and the like. The use of such media and agents for
pharmaceutical active substance is well known in the art. Except insofar as any conventional
media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical
compositions is contemplated. Supplementary active ingredients can also be incorporated into
10 the compositions.

The preferred cytokine for practice of the present invention is OSM. The OSM employed
is preferably as described in United States Patent No. 5,428,012. Preferably, the OSM
comprises an amino acid sequence as set forth in Figure 3 in US Patent No. 5,428,012 or
15 is similar thereto or is a derivative or agonist thereof. In its most preferred form, the OSM
comprises an amino acid sequence which has at least 40%, more preferably at least 50%,
even more preferably at least 60%, still more preferably at least 70-80% and yet even more
preferably at least 90-95%, similarity or identity to one or more regions of the amino acid
sequence set forth in Figure 3 of US Patent No. 5,428,012. The cytokine may also contain
20 single or multiple amino acid insertions, deletions and/or additions to the naturally occurring
sequence and may be derivatised or fragmented to a part carrying the active site of the
cytokine. All such derivatives or fragmented cytokine molecules are encompassed by the
present invention and are included in the expression "cytokine", provided all such molecules
have the effect of altering and preferably reducing growth, proliferation or promoting
25 differentiation of breast cancer cells.

Administration may be by any suitable route such as intravenous, intranasal, subcutaneous,
intraperitoneal, intramuscular, intradermal, infusion, suppository, implant and oral including
slow release capsules. Where cytokines may have a relatively short serum half life, the
30 injected preparation may need to be modified to reduce serum degradation and/or alternative

- 18 -

routes of administration employed. Administration may also be by gene therapy including expression of the particular cytokine gene in vectors which are introduced to the mammal to be treated. Alternatively, the cytokine gene can be expressed in bacteria which are then incorporated into the normal flora of the host.

5

The effective amount of cytokine and particularly OSM will depend on the animal and the condition to be treated. For example, amounts ranging from about 0.1 ng/kg/body weight/day to about 1000 $\mu\text{g}/\text{kg}/\text{body weight}/\text{day}$ are contemplated to be useful in breast cancer therapy. More preferably, the effective amount is 1ng/1kg body weight/day to 100
10 $\mu\text{g}/\text{kg body weight}/\text{day}$. Even more preferably, the effective amount is 10ng/kg body weight/day to 10 $\mu\text{g}/\text{kg body weight}/\text{day}$. Such effective amounts may reflect actual administration protocols or may reflect an average of an alternate administration protocol. The protocol may be varied to administer cytokine or particularly OSM per hour, week or month or in conjunction with other therapeutic agents.

15

In all of the above cases, the present invention also extends to the use of derivatives of cytokines. By derivatives is meant recombinant, chemical or other synthetic forms of OSM or other cytokines and/or any alteration such as addition, substitution and/or deletion to the amino acid sequence component of the molecule or to the carbohydrate or other associated
20 molecule moiety of OSM or other cytokine provided the derivative possesses the ability to alter and particularly to slow growth, proliferation or enhancing differentiation of breast cells. Accordingly, reference herein to OSM or to a cytokine includes reference to its derivatives.

25 The present invention is further described by reference to the following non-limiting Figures and/or Examples.

In the Figures:

Figure 1 is a photographic representation of an analysis of growth factor/receptor expression in breast cancer cells assessed by reverse-transcriptase polymerase chain reaction, RT-PCR. 5
Autoradiograph of RT-PCR products obtained from the analysis of breast cell mRNA. Products were transferred to nylon membranes prior to being probed with a ³²P-labelled oligonucleotide corresponding to the respective growth factor/receptor (Table 1). Lanes 1-12 contain DNA samples from the following cell lines respectively, 184, 184B5, BT-483, MCF-7M, MDA-MB-134, MDA-MB-361, T-47D, BT-20, BT-549, MDA-MB-231, SK-BR-10
3 and HBL-100. Samples in lanes 1 & 2 are from normal breast epithelial cell lines, lanes 3-7 are from estrogen receptor (ER) positive breast cancer cell lines, and lanes 8-12 are from ER negative breast cancer cell lines. Lane 13 is a positive control containing DNA from bone marrow and lane 14 is a negative control in which DNA was omitted from the PCR. Rows A-K represent products detected when the membranes were hybridised to
15 oligonucleotides specific for the following growth factors/receptors respectively, gp130, IL-6R, LIFR, IL-11R, CNTFR, G-CSFR, IL-6, LIF, IL-11, CNTF, G-CSF, OSM and β-ACTIN. Control samples, obtained when reverse transcriptase was omitted from the initial cDNA synthesis of each sample, gave no detected signal.

20 **Figures 2A, B and C** are graphical representations of MCF-7M cells in liquid culture. 10⁴ MCF-7M cells were cultured in 500μl RPMI/10% bovine calf serum (BCS) (v/v) containing the indicated concentration of each of the growth factors (OSM or LIF). After 7 days culture viable cells were counted using a hemacytometer. Cell numbers reported here are the result of one experiment, each performed in triplicate.

25

Figure 3 is a graphical representation showing clonogenicity of MCF-7M cells. Following suspension culture MCF-7M cell viability was measured by agar culture. Cells were plated in agar with the indicated concentrations of each of the growth factors. After 14 days culture colonies of cells were counted. Cell numbers reported here are the results
30 of 3 experiments, each performed in triplicate, and are expressed according to the number

- 20 -

of cells that went into suspension culture.

Figure 4 is a photographic representation showing morphology of growth factor stimulated MCF-7M cells. Following 1 week in suspension culture containing the various growth factors, MCF-7M cells were cytospun onto slides and subsequently stained with Giemsa.

Figures 5A and B are graphical representations of BT-549 cells in liquid culture. 10^4 BT-549 cells were cultured in $500\mu\text{l}$ RPMI/10% (v/v) BCS containing the relevant concentration of each of the growth factors (OSM, IL-11 and IL-6). After 10 days culture viable cells were counted using a hemacytometer. Cell numbers reported here in the two graphs are the results of 1 experiment performed in triplicate.

Figure 6 is a graphical representation of primary normal breast cells in suspension culture. 10^4 primary normal breast cells were cultured in $500\mu\text{l}$ serum free breast media containing the indicated concentration of each of the growth factors (OSM and IL-6). After 7 days culture viable cells were counted using a hemacytometer. Cell numbers reported here are the results of 1 experiment, performed in triplicate.

Figure 7 is a graphical representation showing inhibition of proliferation of MCF-7 cells by Oncostatin M (OSM). 10^4 MCF-7 cells were cultured in $500\mu\text{l}$ RPMI/10% (v/v) BCS with the indicated concentrations of OSM. At 2, 4 and 6 days, viable cells were counted using a hemacytometer. Results are from 3 experiments, each performed in triplicate.

Figure 8 is a graphical representation showing that MCF-7 cells are inhibited in a dose-dependent fashion by Oncostatin M (OSM). 10^4 MCF-7 cells were cultured in $500\mu\text{l}$ RPMI/10% (v/v) BCS with the indicated concentrations of OSM. After 7 days viable cells were counted, and cell number expressed as a percentage of the corresponding untreated control value.

Figure 9 is a graphical representation showing the effect of OSM on cell cycle. MCF-7 cells treated with OSM while growing in serum-free medium were harvested by treatment with trypsin and stained for DNA content analysis by flow cytometry. Cell cycle distributions were calculated by computer fitting of the resultant histograms. Figure 10(a) represents a typical experiment indicating that the percentage of cells in S phase following treatment with OSM decreases from approximately 15 % to 8 % over a 72 hour time period. Figure 10(b) represents data from 2 experiments (performed in triplicate) where the number of cells in S phase are represented as a percentage of the corresponding untreated control value.

10

Figure 10 is a graphical representation showing the effect of EGF and OSM on cell cycle. MCF-7 cells treated with OSM, Epidermal Growth Factor (EGF) or both OSM and EGF while growing in serum-free medium were harvested by treatment with trypsin and stained for DNA content analysis by flow cytometry. Cell cycle distributions were calculated by computer fitting of the resultant histograms. Results represent the combined data from 3 experiments (performed in triplicate) where the number of cells in S phase are represented as a percentage of the corresponding untreated control value.

Figure 11 is a photographic representation showing cell morphology after exposure to OSM. MCF-7 cells from control cultures and appearance of cells after 7 days in OSM. A) Control cells, 10X magnification. B) OSM treated cells, 10X magnification. C) OSM treated cells, 40X magnification. D) OSM treated cells, 100X magnification.

Figure 12 is a photographic representation showing effect of OSM on the expression of Transforming Growth Factor α (TGF α), Epidermal Growth Factor Receptor (EGFR), Prolactin Receptor (PRLR), Estrogen Receptor (ER) and LIF mRNA. Cells growing in the presence of 10% (v/v) BCS were treated with OSM (10ng/ml) and at the indicated time points duplicate 150 cm² flasks were harvested and mRNA extracted for Northern analysis. Results for control cells (C) are also shown. The same filter has been probed successively with a ³²P-labelled cDNA corresponding to each mRNA species. mRNA loading was

- 22 -

evaluated by reprobing the filter with a fragment complementary to GAPDH. mRNA species of the following sizes were obtained: TGF α , 4.8 kb; PRLR, 10.5 and 8.6 kb; EGFR, 10.5 and 5.8 kb; ER, 6.5 and 3.8 kb and LIF, approx. 4.8 kb.

- 5 **Figure 13** is a photographic representation showing ER expression in OSM and EGF treated cells. MCF-7 cells were grown on chamber slides for 6 days in RPMI/10 % (v/v) BCS with the following growth factors, prior to being stained with an antibody specific for ER. A) Control, B) OSM, C) EGF, D) OSM and EGF. Cells stained brown indicate ER positivity.
- 10 **Figure 14** is a photographic analysis of growth factor receptor expression in breast cancer cell lines assessed by RT-PCR. Autoradiograph of RT-PCR products obtained from the analysis of breast cell mRNA. Samples in lanes 1 & 2 are from normal breast epithelial cell lines, lanes 3-7 are from ER positive breast cancer cell lines, and lanes 8-12 are from ER negative breast cancer cell lines. Lane 13 is a positive control containing RNA from bone marrow
- 15 (BM) and lane 14 is a negative control in which RNA was omitted from the PCR (-ve). Products were transferred to nylon membranes prior to being probed with a ³²P-labelled oligonucleotide corresponding to the receptor indicated on the left and β -Actin as a control. Lanes 1-12 contain RNA samples from the following cell lines respectively, 184, 184B5, BT-483, MCF-7M, MDA-MB-134, MDA-MB-361, T-47D, BT-20, BT-549, MDA-MB-231, SK-
- 20 BR-3 and HBL-100. Control samples, obtained when reverse transcriptase was omitted from the initial cDNA synthesis of each sample, gave no signal.

Figure 15 is a photographic representation showing cell morphology after exposure to OSM. MCF-7 cells from control cultures (Panel A) and appearance of cells after culture for 14 days

25 in OSM (10 ng/ml) (Panel B). MDA-MB-231 cells from control cultures (Panel C) and appearance of cells after culture for 7 days in OSM (Panel D).

Figure 16 is a graphical representation showing inhibition of MCF-7 cells after 7 days in suspension culture. 10⁴MCF-7 cells were cultured in 500 μ l RPMI/10% (v/v) BCS with the

30 indicated growth factor. After 7 days viable cells were counted using a hemacytometer.

Results are from 9 experiments, each performed in triplicate.

Figure 17 is a graphical representation showing clonogenicity of MCF-7 cells after 1 week in suspension culture. Following suspension culture clonogenicity of MCF-7 cells was
5 assayed in agar culture. Cells were plated in agar with the indicated growth factor and maintained at 37°C in a humidified incubator with 5% CO₂ in air. After 14 days colonies of cells were counted. Results are from 9 experiments using IL-6, LIF and OSM, and 5 experiments using CNTF and IL-11. Each experiment was performed in triplicate, and colony numbers are expressed as a percentage of untreated controls.

10

Figure 18 is a graphical representation showing BT-549 cells after 10 days in suspension culture. 10⁶ BT-549 cells were cultured in 500µl RPMI/10% (v/v) BCS with the indicated growth factor. After 10 days culture viable cells were counted using a hemacytometer. Results are from 6 experiments, each performed in triplicate.

15

Figure 19 is a graphical representation showing MDA-MB-231 cells after 7 days in suspension culture. 10⁶ MDA-MB-231 cells were cultured in 500µl RPMI/10% (v/v) BCS with the indicated growth factor. After 7 days viable cells were counted using a hemacytometer. Results are from 8 experiments, each performed in triplicate.

20

Figure 20 is a graphical representation showing Scatchard analyses of the saturation isotherms of LIF and OSM binding to breast cancer cell lines. Cells were incubated with various concentrations of labelled or unlabelled ligand in the presence or absence of a 10-100 fold excess of unlabelled ligand. After 18 hr on ice, bound and free ligand were separated by
25 centrifugation through bovine calf serum. Bound and free ¹²⁵I-ligand was quantitated in a γ-counter and the data was depicted as a Scatchard transformation. Data was normalised for cell number and is shown as binding to 10⁶ cells. A) Saturation isotherm of LIF binding to the MCF-7 cell line. This analysis indicates high affinity binding of LIF with a dissociation constant of 14.6 pM and an estimated 57 receptors per cell. B) Saturation isotherm of OSM
30 binding to the MDA-MB-231 cell line. This analysis indicates high affinity binding of OSM

- 24 -

with a dissociation constant of 92 pM and an estimated 124 receptors per cell.

Figure 21 is a photographic analysis of growth factor receptor expression in primary breast cancer tissue assessed by RT-PCR. Autoradiograph of RT-PCR products obtained from the analysis of fresh breast tissue mRNA. Products were transferred to nylon membranes prior to being probed with a ³²P-labelled oligonucleotide corresponding to the respective receptor (Table 2). Lanes 1-15 contain RNA samples representative of the 50 cancerous breast tissue samples obtained at biopsy. These were examined for the growth factor receptors and β -Actin as indicated. Control samples, obtained when reverse transcriptase was omitted from the initial cDNA synthesis of each sample, gave no signal. In some samples (CNTFR, ER and IL-6R) a smaller hybridising PCR product was identified. These bands were attributed to alternative splicing (Koehorst *et al.*, 1993; Horiuchi *et al.*, 1994).

EXAMPLE 1

Breast cell lines

Cell lines 184 (Stampfer and Bartley, 1985) and 184B5 (Walen and Stampfer, 1989) were derived from non malignant breast epithelial cells; BT-483 (Lasfargues *et al.*, 1978), MCF-7M (Soule *et al.*, 1973), MDA-MB-134 (Cailleau *et al.*, 1974), MDA-MB-361 (Cailleau *et al.*, 1978) and T-47D (Keydar *et al.*, 1979) cell lines originated from estrogen receptor (ER) positive breast cancer cells; BT-20 (Lasfargues and Ozzello, 1958), BT-549 (Lasfargues *et al.*, 1978), MDA-MB-231 (Cailleau *et al.*, 1974), SK-BR-3 (Trempe and Fogh, 1973) cell lines originated from ER negative breast cancer cells. The HBL-100 cell line is an ER negative transformed cell line, originating from normal lactating breast (Caron de Fromentel *et al.*, 1985).

- 25 -

EXAMPLE 2

Tissue culture

Breast cell lines were grown in monolayer in RPMI-1640 medium containing 10% (v/v) bovine calf serum ((v/v) BCS) at 37°C in a fully humidified atmosphere, containing 10% (v/v) CO₂ in air. Cell lines were passaged by treatment with 0.05% (w/v) trypsin and 0.02% (w/v) EDTA.

EXAMPLE 3

Reverse transcriptase polymerase chain reaction

Total RNA was extracted from the cell lines and primary breast cancer tissue as previously described (Buckley *et al.*, 1993).

15 First strand cDNA synthesis was performed on 1 µg of total RNA. Reverse transcription was carried out at 42°C for 60 min in 20 µl of 50 mM Tris.HCl pH 8.3, 20 mM KCl, 10 mM MgCl₂, 5 mM dithiothreitol, 1 mM of each dNTP, 20 µg/ml oligo(dT) and 12.5 units of AMV reverse transcriptase (Boehringer Mannheim). Control reactions were performed for each RNA sample under identical conditions except that reverse transcriptase was omitted from the
20 reaction. The reverse transcription reaction mixture was diluted to 100 µl with water and 5 µl was used for each PCR reaction.

PCR reactions were carried out in 50 µl of reaction buffer (Boehringer Mannheim) containing 200 µM of each dNTP, 1 µM of each primer and 2.5 units of Taq polymerase (Boehringer
25 Mannheim). The oligonucleotides used for amplification of cDNA are shown in Table 2. After an initial denaturation of 2 min at 96°C PCR was performed for 30 cycles in a Hybaid Omnigene Thermal Cycler (Integrated Sciences). Each cycle consisted of 30 sec denaturation at 96°C, 30 sec annealing at 60°C and 2 min polymerisation at 72°C. 20 µl of the reaction mixture was electrophoresed on a 1% (w/v) agarose gel and DNA transferred to a nylon
30 membrane (hybond-N+, Amersham). Southern blots were performed as described previously

- 26 -

(Reed and Mann, 1987). Hybridisation was carried out with end-labelled oligonucleotides internal to the respective cDNA sequences (Table 2).

EXAMPLE 4

5

Binding studies

Receptor binding assays were performed using radioiodinated LIF (^{125}I -LIF) and OSM (^{125}I -OSM). The radioiodination of LIF and OSM and binding assays were essentially performed as previously described (Hilton *et al.*, 1991; Hilton and Nicola, 1992). Briefly, 50 μl aliquots
10 containing 1×10^7 cells, suspended in RPMI-1640 medium containing 10% (v/v) BCS, were placed in Falcon tubes with 40 μl of the respective radioiodinated ligand at 1×10^6 cpm per 40 μl , with or without greater than a 40-fold excess of unlabelled ligand. Incubation was carried out at room temperature for 60 min and cells were resuspended and layered over 180 μl of (v/v) BCS. Cell associated and free radioiodinated ligand were separated by
15 centrifugation. The pellet and supernatant were subsequently counted in a γ -counter. Specific binding was estimated by subtraction of non specific binding from binding with ^{125}I -ligand (total binding). Number of cell surface receptors and dissociation constant were calculated by Scatchard analysis.

20

EXAMPLE 5

Biological assays

Proliferation of the cell lines was measured in monolayer culture in 24 well Costar cluster plates. Cells were plated at an initial density of 10 000 cells/ml and cultured in 500 μl RPMI-
25 1640 supplemented with 10 % (v/v) (v/v) BCS and with each growth factor as indicated (LIF, 1000 U/ml; IL-6, 100 ng/ml; OSM, 10 ng/ml; CNTF, 100ng/ml; IL-11, 100ng/ml). These concentrations are maximally active in other systems (Nandurkar *et al.*, 1996; Hilton *et al.*, 1994; Zhang *et al.*, 1994; Tanigawa *et al.*, 1995). After 7 or 10 days at 37°C in a fully humidified atmosphere containing 10% (v/v) CO_2 in air, cells were trypsinised and counted
30 using a haemocytometer and an inverted microscope. Cell viability was assessed using eosin

- 27 -

exclusion. Results were expressed as a percentage of the corresponding untreated control value for that experiment.

EXAMPLE 6

5

Clonogenic assays

Clonogenic potential of cells following monolayer culture was assessed in a semi-solid culture medium. Cells were cultured in triplicate in 35 mm Petri dishes containing 1 ml Iscove's modified Dulbecco's medium (IMDM) supplemented with 25% (v/v) (v/v) BCS, 0.3% (w/v) agar with final
10 concentration of growth factor as outlined above, and with 200 cells per ml for control cultures. Cultures were maintained at 37°C in a humidified incubator with 5% (v/v) CO₂ in air. After 14 days, colonies were enumerated using a dissecting microscope. A colony was defined as a clone of greater than 40 cells. All cultures were performed in triplicate.

15

EXAMPLE 7

Cytokines

Human LIF was produced using the pGEX system, essentially as described (Gearing *et al.*, 1989), human IL-6 was from Ludwig Institute for Cancer Research, (Melbourne, Australia), human CNTF
20 was purchased from AMRAD Operations Ltd. (Melbourne, Australia) and human OSM and IL-11 were purchased from PeproTech (Rocky Hill, NJ, USA).

EXAMPLE 8

Statistical analysis

25

Statistical analysis of data was performed using the paired and unpaired Student's T-test.

- 28 -

EXAMPLE 9**Growth of primary breast tissue**

Sterile normal breast tissue was obtained from reduction mammoplasty surgery. Fat was dissected
5 away and the remaining ductal tissue minced finely, suspended in 'dissociation media'
(DME/Hams F12 containing 10 ng/ml EGF, 1 μ g/ml insulin, 0.5 μ g/ml hydrocortisone, 10 ng/ml
cholera toxin, 300 U/ml collagenase, 100 U/ml hyaluronidase and 1 mg/ml BSA) and agitated
overnight at 37°C . After 18 hours the mixture was centrifuged at 600 RCF/5 min, the
supernatant discarded and the remaining cell pellet washed twice in RPMI-1640 supplemented
10 with 10 % (v/v) (v/v) BCS. An aliquot of the cells was then placed in an 80 cm² tissue culture
flask (Nunc) in 'breast media' (DME/Hams F12 containing 10 ng/ml EGF, 1 μ g/ml insulin, 0.5
 μ g/ml hydrocortisone, 10 ng/ml cholera toxin, 1 mg/ml BSA supplemented with 10% (v/v) (v/v)
BCS) for 24 hour at 37°C in a fully humidified atmosphere, containing 10% (v/v) CO₂ in air.
Single cells adhered to the culture flasks and from these islands of cells epithelial cells grew. The
15 media was subsequently removed and replaced with serum-free breast media. Partial
trypsinisation removed any contaminating fibroblasts and the cells remaining were 95-100%
epithelial. Cells were subsequently grown for approximately 30 days in the serum free breast
media.

20

EXAMPLE 10**Cell Cycle Analysis**

Cell cycle analysis was performed in serum-free medium (Sigma). Analysis was performed 2-4
days after cells were washed and re-cultured in serum-free medium. Growth factors were added
25 to the medium as indicated. At the times shown thereafter, cells were harvested with 0.05 %
(w/v) trypsin-0.02% (w/v) EDTA. The cells were resuspended in serum-free tissue culture
medium and after cell counting using a hemacytometer, stained for later DNA analysis by the
addition of 0.25% prothidium iodide in the presence of 0.2% (v/v) Triton X-100. DNA
histograms were obtained by using a FACScan flow cytometer (Becton Dickinson
30 Immunocytometry Systems) and the cell cycle phase distribution was estimated by using the

- 29 -

manufacturer's DNA analysis software (Cellfit). Each histogram contained 10,000 events.

EXAMPLE 11

RNA isolation and Northern Analysis

5

Cells harvested from duplicate flasks were pooled and poly A+ mRNA extracted by an oligo-dT cellulose procedure (Boehringer Mannheim). Northern analysis was performed using 5 μ g RNA per lane. Membranes (Hybond-C extra-Amersham) were hybridised (42°C overnight) with probes labelled with α -³²P dCTP (bresatec). The membranes were washed at a stringency of 0.2 X SSC (30 mM NaCl, 3 mM sodium citrate, pH 7.0) -0.1% (w/v) sodium dodecyl sulfate at 65°C and exposed to Kodak X-Omat film at -70°C. mRNA loading was estimated by hybridising membranes with a 1.3 kb cDNA complementary to GAPDH.

EXAMPLE 12

15

Analysing growth factor/receptor expression by RT-PCR

Initial experiments have examined expression of several receptors, including gp 130, LIF, G-CSF, GM-CSF, CNTF, IL-2, 3, 6, 7 & 11 and their associated ligands (Figure 1). Preliminary results have indicated the expression of both ligand and receptor in the case of IL-6, LIF and CNTF. The expression of IL-11 receptor was observed in most of the breast samples. The signalling molecule gp130 was also expressed (as expected). The expression of such receptors as G-CSF, GM-CSF and IL-2 appeared to be less consistent in the breast samples.

EXAMPLE 13

25

Function of growth factors/receptors on breast cell growth

The function of the growth factors and receptors identified in initial mRNA and protein studies of breast cancer cells have also been investigated. Breast cell lines were initially examined for changes in cell proliferation in suspension cultures containing the growth factors of interest.

30

- 30 -

Preliminary experiments have examined the growth of several of the breast cancer cell lines in cultures with maximal concentrations of LIF, IL-6 and OSM. These cultures have indicated that two of these growth factors have inhibitory effects on cell proliferation. Figures 2A, 2B and 2C show the proliferation of MCF-7M cells following 1 week in suspension culture. This proliferation data indicates that OSM and LIF may inhibit cell growth. Figure 3 shows the viability of the MCF-7M cells following a clonogenic assay. Results indicate that the effects of the two growth factors are enhanced after this assay.

This inhibition of cell proliferation by OSM has been demonstrated in cell lines MCF-7M and BT549. LIF induced inhibition in cell line MCF-7M. It is interesting to note that IL-6 did not appear to be able to induce inhibition when compared to the control (Figure 2A).

Figure 4 depicts four photomicrographs of MCF-7M breast cancer cells treated with maximal concentrations of IL-6, OSM and LIF for 1 week in liquid culture. Cells grown in the presence of IL-6 appeared morphologically similar to the control; several of the cells grown in LIF appeared larger than the control cells; the cells grown in the presence of OSM showed more abundant cytoplasm and vacuolation. This morphological change in the OSM treated cells was consistent with features of cell differentiation. These findings suggested that ligand-induced growth inhibition in breast cancer cell lines may be associated with an apparent induction of differentiation.

Figures 5A and 5B show cells from the BT-549 cell line that have been grown in liquid culture in the presence of IL-11. As well as the growth inhibition seen previously on other cell lines with OSM, the BT-549 cell proliferation was inhibited by IL-11.

25

EXAMPLE 14**Examination of breast tissues**

The inventors developed culture techniques that allow the growth of normal breast cells *in vitro*.
5 A total of 4/4 normal breast samples have been successfully cultured and continued to proliferate for several weeks.

RT-PCR analysis from three of these primary normal breast samples have indicated that gp 130, LIFR, LIF and OSM are expressed in these cells. Figure 6 shows the growth of one of these
10 primary samples in suspension culture with the various growth factors. These data show that OSM profoundly inhibited the proliferation of these normal cells.

EXAMPLE 15**Inhibition of proliferation of MCF-7 cells by Oncostatin M (OSM).**

15

The results are shown in Figure 7. 10^4 MCF-7 cells were cultured in 500 μ l RPMI/10% (v/v) BCS with the indicated concentrations of OSM. At 2, 4 and 6 days, viable cells were counted using a hemacytometer. Results are from 3 experiments, each performed in triplicate. These data demonstrate that while control cells grow in an exponential fashion over the 6 day time period,
20 there was inhibition of cellular proliferation as a result of treatment with OSM.

EXAMPLE 16**MCF-7 cells are inhibited in a dose-dependent fashion by Oncostatin M (OSM).**

25 The results are shown in Figure 8. 10^4 MCF-7 cells were cultured in 500 μ l RPMI/10% (v/v) BCS with the indicated concentrations of OSM. After 7 days viable cells were counted, and cell number expressed as a percentage of the corresponding untreated control value. Results are from 5 experiments each performed in triplicate. Results indicate that treatment of MCF-7 cells with pg/ml quantities of OSM results in decreases in cellular proliferation while a concentration of 10
30 ng/ml OSM results in optimal inhibition.

- 32 -

EXAMPLE 17**Effect of OSM on cell cycle.**

The results are shown in Figure 9. MCF-7 cells treated with OSM while growing in serum-free
5 medium were harvested by treatment with trypsin and stained for DNA content analysis by flow
cytometry. Cell cycle distributions were calculated by computer fitting of the resultant
histograms. Figure 9A represents a typical experiment indicating that the percentage of cells in
S phase following treatment with OSM decreases from approximately 15 % to 8 % over a 72 hour
time period. Figure 9B represents data from 2 experiments (performed in triplicate) where the
10 number of cells in S phase are represented as a percentage of the corresponding untreated control
value. At the initial time point of 12 hour there is a marked decrease in the S phase cells in OSM
treated cells. By 24 hour the number of cells in S phase was 50 % of control cells. There was
a concomitant increase in the percentage of cells in G₁ phase, demonstrating that OSM is
inhibiting a rate limiting step in progression through G₁. Similar results were seen when cells
15 were grown in RPMI containing 10 % (v/v) BCS.

EXAMPLE 18**Effect of EGF and OSM on cell cycle.**

20 The results are shown in Figure 10. MCF-7 cells treated with OSM, Epidermal Growth Factor
(EGF) or both OSM and EGF while growing in serum-free medium were harvested by treatment
with trypsin and stained for DNA content analysis by flow cytometry. Cell cycle distributions
were calculated by computer fitting of the resultant histograms. Results represent the combined
data from 3 experiments (performed in triplicate) where the number of cells in S phase are
25 represented as a percentage of the corresponding untreated control value. The S phase fraction
is decreased in cells treated with OSM, and this is maintained over a 6 day time period. Cells
treated with EGF (thought to be a mitogenic stimuli in some breast cancers) and OSM also
demonstrate a 50 % decrease in S phase fraction.

- 33 -

EXAMPLE 19**Cell morphology after exposure to OSM.**

The results are shown in Figure 11. MCF-7 cells from control cultures and appearance of cells
5 after 7 days in OSM. A) Control cells, 10X magnification. B) OSM treated cells, 10X
magnification. C) OSM treated cells, 40X magnification. D) OSM treated cells, 100X
magnification. Striking changes in the morphology of cells treated with OSM are apparent.
MCF-7 cells exposed to OSM appeared to draw apart from neighbouring cells, and to develop a
more fibroblastic phenotype. This was associated with the appearance of decreased intercellular
10 adhesion and the development of pseudopodia-like processes.

EXAMPLE 20

Effect of OSM on the expression of Transforming Growth Factor α
(TGF α , Epidermal Growth Factor Receptor (EGFR), Prolactin Receptor
15 **(PRLR), Estrogen Receptorm (ER) and LIF mRNA.**

The results are shown in Figure 12. Cells growing in the presence of 10% (v/v) BCS were
treated with OSM (10ng/ml) and at the indicated time points duplicate 150 cm² flasks were
harvested and mRNA extracted for Northern analysis. Results for control cells (C) are also
20 shown. The same filter has been probed successively with a ³²P-labelled cDNA corresponding to
each mRNA species. mRNA loading was evaluated by reprobing the filter with a fragment
complementary to GAPDH. mRNA species of the following sizes were obtained: TGF α , 4.8 kb;
PRLR, 10.5 and 8.6 kb; EGFR, 10.5 and 5.8 kb; ER, 6.5 and 3.8 kb and LIF, approx. 4.8 kb.

25 Northern analysis demonstrates that as a result of cells being exposed to OSM the abundance of
EGFR mRNA is elevated at least 5-fold between 4-12 hours. The EGFR transcript decreases to
control levels by 24 hour. The abundance of Transforming Growth Factor α (TGF α) transcript
in OSM treated cells appears to be equivalent to control cells over this time period. However,
OSM appears to down regulate the level of expression of both Estrogen Receptor (ER) and
30 Prolactin Receptor (PRLR) mRNA. After only 2 hours exposure to OSM the levels of these two

- 34 -

receptors is down regulated and this is maintained for 48 hours. OSM also upregulates the level of LIF transcript in MCF-7 cells over the 1-4 hour time period.

EXAMPLE 21

5

ER expression in OSM and EGF treated cells.

The results are shown in Figure 13. MCF-7 cells were grown on chamber slides for 6 days in RPMI/10 % (v/v) BCS with the following growth factors, prior to being stained with an antibody specific for ER. A) Control, B) OSM, C) EGF, D) OSM and EGF. Cells stained brown indicate ER positivity. Results indicate that 90 % of control cells have stained positive for ER and cells treated with EGF have approximately 60 % ER positivity. Cells treated with OSM show 50 % of cells staining very weakly for ER, indicating a down regulation of ER protein levels after treatment with OSM. Furthermore, this down regulation of ER protein is more dramatic when cells are treated with both OSM and EGF as only approximately 10 % of cells have stained positively for ER. Morphologically it can be seen that cells treated with OSM appear larger and more vacuolated than control cells. The morphological changes are more striking when cells are treated with OSM and EGF: cells are larger than control cells and have more abundant cytoplasm and cytoplasmic processes.

20

EXAMPLE 22

RT-PCR analysis of receptor expression on breast cancer cell lines

Initial experiments examined the expression of various receptors on 12 breast cell lines. These receptors included the LIF receptor (LIFR), IL-6R, IL-11R, CNTFR, the common gp130 signalling molecule and receptors for IL-2, 3, 6, 7 & 11, G-CSF, GM-CSF, growth hormone (GH) and prolactin (PRL) (Figure 14). Both GHR and PRLR were expressed primarily in estrogen receptor (ER) positive cell lines with inconsistent expression in ER negative cells. GHR was also expressed in the breast cell lines derived from normal tissue, whereas PRLR was not expressed in these cells.

30

- 35 -

All cell lines expressed the signalling molecule gp130, and expression of the specific receptor components for IL-6, LIF, IL-11 and CNTF was observed in the majority of cell lines studied. Expression of the LIFR was ubiquitous and appeared equivalent to the level of gp130 as assessed by RT-PCR. IL-11R expression was also observed in all of the cell lines except SK-BR-3 (a line
5 originating from an ER negative breast carcinoma). However, expression of the IL-6R in the cell lines appeared variable, consistent with the variable biological effects reported for IL-6. For example expression of the IL-6R in MCF-7, T-47D and SKBR3 cell lines is consistent with previous reports of variable effects of IL-6 in these cell lines. Equally the lack of IL-6R expression in the MDA-MB-231 cell line correlates well with reports describing its lack of activity on these
10 cells (Danforth and Sgagis, 1993).

The CNTFR was readily detected in cell lines that expressed the ER, but with no expression observed in cell lines derived from normal breast nor ER negative cell lines. The pattern of expression was thus similar to PRLR expression.

15

In contrast to the widespread expression of gp130 and associated receptors, expression of receptors for G-CSF, GM-CSF, IL-2 and IL-3 was highly variable in these breast cell lines. G-CSFR was expressed only in the BT-483 cell line. While the β common signalling subunit shared by GM-CSF, IL-3 and IL-5 was detected in 6 cell lines the specific GM-CSFR α and IL-3R α chains were
20 expressed in only 2 cell lines. The IL-2R γ common signalling subunit, shared by IL-2, 4, 7, 9 and 13, was expressed in 2 of the breast cell lines, while for example, the IL-7R α chain was not expressed in any cell lines.

Because of the widespread expression pattern of the gp130 molecule and associated receptors in
25 the majority of breast cell lines compared with the variable expression of other cytokine receptors, we elected to focus on the gp130 sub-family in this study.

- 36 -

EXAMPLE 23

Action of cytokines on growth of breast cell lines

The action of IL-6, LIF, OSM, CNTF and IL-11 was examined on 4 breast cancer cell lines grown
5 in monolayer culture. Striking changes in the morphology of cells were observed. Figure 15
compares morphology of untreated cells with cells exposed to OSM. MCF-7 cells exposed to OSM
appeared to draw apart from neighbouring cells, and to develop a more fibroblastic phenotype. This
was associated with the appearance of decreased intercellular adhesion or cellular contraction.
These changes were quite marked by day 14. Transformation to a fibroblastic phenotype was also
10 observed in the BT-549 and MDA-MB-231 cell lines exposed to OSM, with elongation of cells
and loss of intercellular contact. In contrast, T-47D cells cultured with OSM, became more rounded
in appearance.

Experiments were performed to determine whether these morphological changes were associated
15 with alterations in cell growth. The proliferation of four breast cancer cell lines was examined in
monolayer cultures containing either IL-6, LIF, OSM, CNTF or IL-11. In this assay, significant
inhibition of cellular proliferation by OSM in 3/4 cell lines, IL-11 in 2/4 cell lines and by IL-6 and
LIF in 1/4 cell lines was observed.

20 The MCF-7 cell line exhibited a biological response following treatment with this family of growth
factors. Results of 9 experiments examining action of IL-6, LIF and OSM, and 5 experiments
examining action of CNTF and IL-11 on the MCF-7 cell line are presented in Figure 16. In control
cultures of MCF-7 cells the absolute cell number increased from $10^4/\text{ml}$ to $5 \times 10^4 - 1.1 \times 10^5/\text{ml}$ during
the 1 week culture period. The most dramatic effect on cell proliferation was seen after 7 days
25 exposure to OSM, with up to 94% inhibition and a mean of 85% inhibition in 9 experiments ($p < 0.001$).
This action of OSM was maximal at concentrations of greater than 10 ng/ml. Exposure
to LIF for 7 days resulted in an average of 37% growth inhibition ($p < 0.01$). The effect of IL-11
and IL-6 was less marked. The mean inhibition observed in response to IL-6 was 23% ($p < 0.01$).
In five experiments using IL-11 a mean of 27% inhibition ($p = 0.02$) was observed. In contrast,
30 there was no effect on cellular proliferation in five experiments in which cells were treated with

- 37 -

CNTF.

To further address the inhibitory effect of these molecules on MCF-7 cells we also examined the clonogenic potential of cells following growth in monolayer cultures for 7 days. The frequency of
5 clonogenic MCF-7 cells in control cultures was 20-60% (n=9 experiments). With OSM, LIF and IL-6 the growth inhibitory effect observed in monolayer culture were also detected in agar cultures. Results of 9 experiments (Figure 17) showed significant reduction of colony formation by cells which had been exposed to IL-6 ($p < 0.01$), LIF ($p < 0.01$) and OSM ($p < 0.01$). In 5 experiments exposure to IL-11 in monolayer culture did not have detectable effect on subsequent clonogenicity
10 ($p = 0.65$). As in the monolayer cultures, exposure to CNTF had no effect on clonogenic potential of these cells.

Results of treatment of the cell line BT-549 with growth factor for 10 days are presented in Figure 18 (n=6 experiments). The number of BT-549 cells in control cultures increased from 10^4 /ml to 4-
15 9×10^4 /ml during the 10 day culture period. Mean growth inhibition of 60% followed treatment with OSM, with up to 80% inhibition observed ($p < 0.01$). This inhibition was also apparent at 7 days (mean 60%, $p < 0.01$). Similarly, inhibition of up to 63% (mean 56%, $p < 0.01$) in response to IL-11 was observed at 10 days however after 7 days in culture this effect was less evident (mean 30%,
20 $p = 0.17$). As expected from the results shown in Figure 14 with no detectable mRNA for IL-6R and very low levels of CNTFR mRNA.

Figure 19 depicts 8 experiments using the ER negative cell line, MDA-MB-231. Inhibition of proliferation of up to 65% (mean 54%, $p < 0.01$) was observed in cells exposed to OSM. Treatment with LIF did not result in significant effects on cellular proliferation. These cells did not express
25 CNTFR (Figure 14) and did not respond to CNTF. Similarly the level of IL-6R expression was barely detectable (Figure 14).

EXAMPLE 24**Analysis of receptor protein expression**

The response of BT-549 and MDA-MB-231 cells to OSM but not to LIF was unexpected given that
5 both growth factors utilize the LIF-gp130 heterodimer. Experiments were, therefore, performed
to document LIFR expression and binding of LIF to the surface of these cells. Binding assays were
performed to monitor incorporation of the respective radio-labelled ligand. Four breast cancer cell
lines (T-47D, MDA-MB-231, MCF-7 and HBL-100) were examined with ¹²⁵I-LIF and ¹²⁵I-OSM.
Table 3 shows the specific binding of OSM and LIF. All four of the cell lines demonstrated specific
10 binding. Three of the cell lines showed increased binding of OSM compared with LIF. Binding
of radiolabelled LIF was comparable for all cell lines. In contrast there was approximately 10-fold
reduced binding of radiolabelled OSM to HBL-100 cells compared with the other cell lines (a cell
line derived from normal lactating breast). Thus the failure of BT-549 cells and MDA-MB-231
cells to respond to LIF could not be attributed to lack of expression of LIFR mRNA (Figure 14) nor
15 to lack of receptor protein expression (Table 3).

Binding of ¹²⁵I-LIF to the MCF-7 cell line (Figure 20A) revealed a single class of high affinity
binding sites for LIF with an estimated 57 receptors per cell and a dissociation constant of 14.6 pM.
In contrast, and in keeping with the results presented in Table 3, MCF-7 cells showed an estimated
20 990 receptors per cell and a dissociation constant of 2 nM for ¹²⁵I-OSM. Results obtained with the
HBL-100 cell line also demonstrated high affinity binding of ¹²⁵I-LIF. HBL-100 cells showed an
estimated 27 receptors per cell and a dissociation constant of 7.49 pM. The number of LIF binding
sites observed on these cells is comparable with estimates of receptor number for other tissues
(Hilton *et al.*, 1991). Figure 21B shows a Scatchard analysis depicting binding of ¹²⁵I-OSM to the
25 MDA-MB-231 cell line. MDA-MB-231 cells also showed a single class of high affinity binding
sites for OSM, with an estimated 124 receptors per cell and a dissociation constant of 92 pM.

EXAMPLE 25**Receptor expression by RT-PCR on primary breast cancer samples**

Based on the aforementioned results, the inventors sought to determine whether the gp130 sub-
5 family of receptors might also be expressed on fresh tumor samples. Although it was possible that these receptors might be expressed on normal breast cells contaminating these tissue samples, the concordance between results from primary samples and analysis of cell lines suggested that this was not the case.

10 Typical results for expression of the gp130 sub-family of receptors from 50 clinical samples of malignant breast tissue are shown in Figure 21. This analysis showed a strikingly similar pattern of expression of gp130 associated receptors to that observed on breast cancer cell lines. Expression of gp130, LIF and IL-11 receptors was detected on 96%, 96% and 98% of the samples respectively. By comparison, IL-6 receptor was detected in only 80% of the samples. This was consistent with
15 the variable expression pattern of this receptor relative to LIF and IL-11 receptors that was observed on cell lines. CNTFR expression was observed in 94% of the primary breast cancer samples. This was more frequent than CNTFR expression in the cell lines, and the correlation with ER (only 68% of samples were ER positive) was less marked. It was interesting, however, that the three samples that were CNTFR negative were also ER negative. Thus the widespread expression
20 of members of the gp130 sub-family of receptors was observed not only in breast cancer cell lines but in the majority of samples obtained from malignant breast tissue.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that
25 the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

TABLE 2

Sequence of Oligonucleotides

Gene	size cDNA (bp)	5' sequence/3' sequence (5'-3')	internal sequence (5'-3')	Reference
gp 130	811	GAGGTGTGAGTGGGATGGTG GCTGCATCTGATTTGCCAAC'	GGGCAACACACAAGTTTGCTGATTG'	Hibi <i>et al.</i> , 1991
IL-6R	748	GTTTCAGAACAGTCCGGCCG CTTGCCCTTCGTTCCAGAGCCC'	CAGGAGCCGTGCCAGTATCCAGG'	Yamasaki <i>et al.</i> , 1988
LIFR	660	CCCTCTGGAACAGGCCGTGG CAAGGGCAGTTTGTATGGCC'	GAAAGTTGCATTGAAAACAGGTCCCG'	Gearing <i>et al.</i> , 1991
IL-11R	509	CTGAGTCTGGAGCCAGTAC GGTGTGTTGGAGGGAGGGC'	GTGACTGAGGTGAACCCACTGGGTG'	Nandurkar <i>et al.</i> , 1996
CNTRF	649	GTGGCCCTGCTGTGTGC CCAGCCGGCGAGGGTTGCTG ⁹	CGCCCGCAGTTGTCTACGCCCCAGAG ¹⁰	Davis <i>et al.</i> , 1991
G-CSFR	1034	GCTGCATCTAAAGCACATTG GAGATGGTGAGAGCCTGGGCTG ¹¹	GACCTGGGCACAGCTGGAGTGGGTG ¹²	Fukunaga <i>et al.</i> , 1990
PLR	670	CAGACTACATAACCCGGTGGC TGGCATCCCAAGGCACCTCAG ¹³	CAAGCAGTACACCTCCATGTGGAGG ¹⁴	Boutin <i>et al.</i> , 1989
GHR	702	CAGATCCACCCATTGCCCTC CGCCATCCTTCACCCCTAGG ¹⁵	GGCGAGTTCAGTGAGGTGCTCTATG ¹⁶	Leung <i>et al.</i> , 1987

TABLE 2 (continued...)

GM-CSFR β 710	CCACCAGGTACTGGCCAGG GAGGACCAGTTGCACCTGC ¹⁷	GCACCGGCTACAACGGGATCTGGAG ¹⁸	Hayashida <i>et al.</i> , 1990
GM-CSFR α 928	GGAAGGGAGGTACCGCTGC CTTGACCACCACCCCTGCCTC ¹⁹	CTGTACCTGGCGAGGGTCCGACG ²⁰	Crosier <i>et al.</i> , 1991
IL-2R γ 776	CCCCTCCCAGAGGTTCA GTG AGACACACCACTCCAGGCCG ²¹	CAGCAGCTCTGAGCCCCCAGCCTACC ²²	Takeshita <i>et al.</i> , 1992
IL-3R α 888	GCCGACTATTCTATGCCGGC CGTTTTGGAAGCTGTACCCG ²³	CCGTCCGAGTGGCCCAACCCACCAATT ²⁴	Kitamura <i>et al.</i> , 1991
ER 711	GTGTACAAC TACCCCGAGGG CTCATGTCTCCAGCAGACCC ²⁵	CGCCAACGGCCAGGTCTACGGTCAG ²⁶	Green <i>et al.</i> , 1986
β -ACTIN 721	CTTCCCCTCCATCGTGGGC GTTTCGTGGATGCCACAGGAC ²⁷	CGACGAGGCCCAAGAGAGAGGC ²⁸	Ponte <i>et al.</i> , 1984

1-28 Corresponds to SEQ ID Nos. 1-28

- 42 -

TABLE 3
BINDING OF hOSM AND hLIF TO HUMAN BREAST CANCER CELL LINES

Cell line	specific binding(cpm)/10 ⁶ cells	
	OSM	LIF
T47D	1400+/-20	380+/-10
MDA-MB-231	2980+/-460	450+/-120
MCF-7M	1250+/-90	350+/-100
HBL-100	140+/-10	590+/-30

BIBLIOGRAPHY:

Antman, K. H. 1992. Dose intensive therapy in breast cancer. In Armitage, JO and Antman, KH, eds., High-dose cancer therapy: Pharmacology, Hematopoietins, stem cells. Williams & Williams, Baltimore; 701-718.

Ardizzoni A. *et al.* 1994. Br J Cancer 69: 385-391.

Balawadger I., Antich P. P., Bland J. 1983. Cancer 51: 574.

Basser R. L. *et al* 1995. Clin Can Res. 1:715-721.

Bonadonna G. and Valagussa P. 1981. N Eng J Med 304: 10-15.

Bronchud M. H. *et al.* 1989. Br J Cancer 60: 121-125.

Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A. and Sutherland, R. L. (1993) Oncogene, 8: 2127-2133.

Cailleau R., Olive, M. and Cruciger, J. (1978) In vitro, 14: 911-915.

Cailleau R., Young, R., Olive, M. and Reeves, W. J. (1974) J. Natl. Cancer. Inst., 53: 661-674.

Cailleau R. *et al.* 1974. J Natl Cancer Inst 53: 661-674.

Cailleau R. *et al.* 1978. In vitro 14: 911-915.

Carmo-Pereira J. *et al.* 1987. Br J Cancer 56: 471-473.

- Caron de Fromental, C., Nardeux, P. C., Soussi, T., Laviolle, C., Estrade, S., Carloni, G., Chandrasekaran, K. and Cassingera, R. (1985) *Exptl. Cell. Res.*, 160: 83-94.
- Chen, L. *et al.* 1991. *J Biol Regulators and Homeostatic agents*. 5(4):125.
- Chrysogelos, and Dickson, R. 1994. *Breast Cancer Res Treat* 29: 29.
- Davis S. *et al.* 1991. *Science* 253: 59-63.
- Danforth, D. N. and Sgagias, M. K. (1993) *Cancer Res.*, 53: 1538-1545.
- Dedhar, S. *et al.* 1988. *PNAS* 9253.
- Dickson, R. B. and Lipmann M. E. 1992. *Semin Oncol.* 19:286.
- Early Breast Trial Collaborative Group. *Lancet* 1992; 339(1):71.
- Eddy D. M. 1992. *J Clin Oncol* 10: 657-670.
- Ethier, S. P. *et al.* 1993. *Cancer Res* 53: 627.
- Ferguson J. E. *et al.* 1993. *Br J Cancer* 67: 825-829.
- Fisher B., Slack N. H., Bross I. D. H. 1969. *Cancer* 24: 1071.
- Focan C. *et al.* 1993. *J Clin Oncol* 11: 1253-1263.
- Fukunaga R. *et al.* 1990. *PNAS USA* 87: 8702-8706.
- Gearing, D. P., King, J. A., Gough, N. M. and Nicola, N. A. (1989) *EMBO J*, 8: 3667-3676.

Gearing *et al.* 1991. EMBO J 10: 2839-2848.

Gearing, D. P. *et al.* 1992. Sci 255: 1434.

Gianni A. M. *et al.* 1992. Pro Am Soc Clin Oncol 11: 60.

Green, A. R. *et al.* 1991. EMBO J 10: 4153.

Haagensen, C. D. 1986. Diseases of the breast (ed 3). Philadelphia, WB Saunders, p 635.

Halstead W. S. 1907. Ann Surg 46: 1.

Harris, A. L. 1994. Breast Cancer Res Treat 29: 1 .

Hibi M. *et al.* 1991. Cell 63: 1149-1157.

Hilton, D. J., *et al.* 1991. J Cell Phys 146: 207.

Hilton D. J. and Nicola N. A. 1992. J Biol Chem 267: 10238-10247.

Hilton, D. J., Hilton, A. A., Raicevic, A., Rakar, S., Harrison-Smith, M., Gough, N. M., Begley, C. G., Metcalf, D., Nicola, N. A. and Willson, T. A. (1994) EMBO J, 13(20): 4765-4775.

Hilton, D. J. and Nicola, N. A. (1992) J. Biol. Chem., 267: 10238-10247.

Hilton, D. J., Nicola, N. A. and Metcalf, D. (1991) J. Cell Phys., 146: 207-215.

- Horiuchi, S., Koyanagi, Y., Zhou, Y., Miyamoto, H., Tanaka, Y., Waki, M., Matsumoto, A., Yamamoto, M. and Yamamoto, N. (1994) *Eur. J. Immunol.*, 24: 1945-1948.
- Hoekman K. *et al.* 1991. *J Natl Cancer Inst* 83: 1546-1553.
- Hrynuik W. and Bush H. 1984. *J Clin Oncol* 2: 1281-1288.
- Hrynuik W. and Levine M. N. 1986. *J Clin Oncol* 4: 1162.
- Jain K. K., Casper E. S. *et al.* 1985. *J Clin Oncol* 3: 818-826.
- Jones R. B. *et al.* 1987. *J Clin Oncol* 5(2): 172-177.
- Kacinski B. M. *et al.* 1991. *Oncogene* 6: 941-952.
- Keydar I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S. and Brenner, H. J. (1979) *Eur. J. Cancer*, 15: 659-670.
- Koehorst, S. G. A., Jacobs, H. M., Thijssen, J. H. and Blankenstein, M. A. (1993) *J. Steroid Biochem. Mol. Biol.*, 43: 227-233.
- Komminoth P and Long AA. 1993. *Virchows, Archiv B Cell Pathol.* 64:67.
- Lalisang, R. *et al.* 1994. *Pro Am Soc Clin Oncol* 13: 60.
- Lasfargues E.Y. and Ozello L. 1958. *J Natl Cancer Inst* 21: 1131-1147.
- Lasfargues E.Y. *et al.* 1978. *J Natl Cancer Inst* 61: 967-978.
- Li, S. *et al.* 1992. *J Cell Physiol.*153: 103.

- 47 -

Malik N. *et al.* 1989. *Mol Cell Biol* 9: 2847-2853.

Marchner N. *et al.* 1994. *Semin Oncol* 21(Suppl 1): 10-16.

Moreau J. F. *et al.* 1988. *Nature* 336: 690-692.

Musgrove, E. A. *et al.* 1994. *PNAS* 91: 8022.

Nandurkar, H. H., Hilton, D. J., Nathan, P., Willson, T., Nicola, N. and Begley, C. G. (1996) *Oncogene*, 12: 585-593.

Negata S. *et al.* 1986. *Nature* 319: 415-418.

Negro A. *et al.* 1991. *Eur J Biochem* 201: 289-294.

Nemoto, T., Vana J., Bedwani R. N., *et al.* 1980. *Cancer* 45: 2917.

Neri B. *et al.* 1993. *Cancer Invest* 11: 106-112.

Nuovo G. J. *et al.* 1991. *Am J Pathol* 139(4): 847-854.

Osborne, L. K. 1991. In Harris J. R. *et al.* (eds). *Breast Diseases*, ed 2. Philadelphia, J.B. Lippincott, p.301.

Paul S. R. *et al.* 1990. *PNAS USA* 87: 7512-7516.

Peters W. P. *et al.* 1993. *J Clin Oncol* 11: 1132-1143.

Petersen, O. W. *et al.* 1992. *PNAS* 89: 9064.

- 48 -

- Piccart M. J. *et al.* 1995. *Ann Oncol* 6: in press.
- Ponte P. *et al.* 1984. *Nucl Acids Res* 12:1687-1696.
- Reed K. C. and Mann D. A. 1987. *Nucl Acids Res* 13: 7207-7221.
- Rozenzweig M. *et al.* 1984. *J Clin Oncol* 2: 275-286.
- Saiki, R. K. *et al.* 1985. *Sci* 223: 487.
- Scinto A. F. *et al.* 1995. *Ann Oncol* 6: in press.
- Siegall, C. B. *et al.* 1990. *Cancer Research* 50: 7786-7788.
- Soule H.D. *et al.* 1973. *J Natl Cancer Inst* 51: 1409-1413.
- Stampfer, M. R. and Bartley, J. C. (1985) *Proc. Natl. Acad. Sci. USA*, 82: 2394-2398.
- Stampfer, M. R. and Yaswen, P. 1993. *Cancer Surveys* 18: 7.
- Tang, R. *et al.* 1990. *J Cell Biochem.* 44: 189.
- Tanigawa, T., Nicola, N., McArthur, G. A., Strasser, A. and Begley, C. G. (1995) *Blood*, 85(2): 379-390
- Tannock I. *et al.* 1988. *J Clin Oncol* 6: 1377-1387.
- Todd N. W. *et al.* 1993. *Am Rev Respir Dis* 147: 1264-1270.
- Trempe G. and Fogh J. 1973. *In vitro* 8: 433.

Valagussa P., Bonadonna G., Veronesi U. 1978. Tumori 64: 241.

Van Oosterrom A. T. 1987. Clin Trials J 24: 131-137.

Walen K. and Stampfer M.R. 1989. Cancer Genetics and Cytogenetics 37: 249-261.

Wong G. *et al.* 1988. Behring Inst Mitt 83: 40-47.

Wood W. C. *et al.* 1994. N Eng J Med 330: 1253-1259.

Yamasaki K. *et al.* 1988. Science 241: 825-828.

Zhang, X., Gu, J., Lu, Z., Yasukawa, K., Yancopoulos, G. D., Turner, K., Shoyab, M., Taga, T.,
(v/v) BCS, T., Bataille, R. and Klein, B. (1994) J. Exp. Med., 177: 1337-1342.

- 50 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: (Countries other than US) AMRAD OPERATIONS PTY LTD
(US only) DOUGLAS, AM and BEGLEY, CG
- (ii) TITLE OF INVENTION: A METHOD OF TREATMENT
- (iii) NUMBER OF SEQUENCES: 28
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DAVIES COLLISON CAVE
 - (B) STREET: 1 LITTLE COLLINS STREET
 - (C) CITY: MELBOURNE
 - (D) STATE: VICTORIA
 - (E) COUNTRY: AUSTRALIA
 - (F) ZIP: 3000
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT INTERNATIONAL
 - (B) FILING DATE: 25-OCT-1996
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: PN6242
 - (B) FILING DATE: 27-OCT-1995
 - (A) APPLICATION NUMBER: PN6243
 - (B) FILING DATE: 27-OCT-1995
 - (A) APPLICATION NUMBER: PN8966
 - (B) FILING DATE: 27-MAR-1996
 - (A) APPLICATION NUMBER: PO0364
 - (B) FILING DATE: 07-JUN-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: HUGHES DR, E JOHN L
 - (C) REFERENCE/DOCKET NUMBER: EJH/EK
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: +61 3 9254 2777
 - (B) TELEFAX: +61 3 9254 2770

- 51 -

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 51 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGGTGTGAG TGGGATGGTG GGCTGCATCT GATTTGCCAA C

51

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGGCAACACA CAAGTTTGCT GATTG

25

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GTTTCAGAAC AGTCCGGCCG CTTGCCTTCG TTCAGAGCCC

50

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 52 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CAGGAGCCGT GCCAGTATTC CCAGG

25

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCCTCTGGAA CAGGCCGTGG CAAGGGGCAG TTTGTATGGC C

51

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAAGTTTGCA TTGAAAACAG GTCCCG

26

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTGAGTTCTG GAGCCAGTAC GGTGTGGTTG GAGGGAGGGC

50

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 53 -

- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
- GTGACTGAGG TGAACCCACT GGGTG** 25
- (2) INFORMATION FOR SEQ ID NO:9:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
- GTGGGCCTGC TGTGCTGTGC CCAGCCGGCG AGGGTTGCTG** 50
- (2) INFORMATION FOR SEQ ID NO:10:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
- CGCCGCAGTT GTCTACGCC AGAG** 24
- (2) INFORMATION FOR SEQ ID NO:11:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 52 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
- GCTGCATCTA AAGCACATTG GAGATGGTGA GAGCCTGGGC TG** 52
- (2) INFORMATION FOR SEQ ID NO:12:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid

- 54 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GACCTGGGCA CAGCTGGAGT GGGTG

25

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAGACTACAT AACCGGTGGC TGGCATCCCA AGGCACTCAG

50

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CAAGCAGTAC ACCTCCATGT GGAGG

25

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CAGATCCACC CATTGCCCTC CGCCATCCTT CACCCCTAGG

50

- 55 -

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGCGAGTTCA GTGAGGTGCT CTATG

25

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CCACCAGGTA CTGGGCCAGG GAGGGACCAG TTGCACCTGC

50

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GCACCGGCTA CAACGGGATC TGGAG

25

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 56 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGAAGGGAGG GTACCGCTGC CTTGACCACC ACCCTGCCTC

50

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CTGTACCTGG GCGAGGGGTC CGACG

25

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCCCTCCCAG AGGTTTCAGTG AGACACACCA CTCCAGGCCG

50

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CAGCAGCTCT GAGCCCCAGC CTACC

25

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 57 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GCCGACTATT CTATGCCGGC CGTTTTGGAA GCTGTCACCG

50

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCGTCCGAGT GGCCAACCCA CCATT

25

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GTGTACAACT ACCCCGAGGG CTCATGTCTC CAGCAGACCC

50

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CGCCAACGCG CAGGTCTACG GTCAG

25

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid

- 58 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CTTCCCCTCC ATCGTGGGGC GTTTCGTGGA TGCCACAGGA C

51

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CGACGAGGCC CAGAGCAAGA GAGGC

25

CLAIMS:

1. A method for the treatment or prophylaxis breast cancer in a mammal, said method comprising administering to said mammal an effective amount of one or more cytokines or functional derivatives or agonists of said one or more cytokines for a time and under conditions sufficient to ameliorate the effects of or to delay onset of said cancer.
2. A method according to claim 1 wherein the cytokines are selected from the list consisting of oncostatin M (OSM), interleukin-6 (IL-6), interleukin-11 (IL-11), leukaemia inhibitory factor (LIF) and epidermal growth factor (EGF) or other members of the EGF family.
3. A method according to claim 1 wherein the cytokine is OSM.
4. A method according to claim 1 wherein the cytokine is LIF.
5. A method according to claim 2 or 3 or 4 wherein the cytokine is of human or murine origin.
6. A method according to claim 1 or 2 wherein the breast cancer is metastatic breast cancer.
7. A method according to claim 1 or 2 wherein the breast cancer is early breast cancer.
8. A method according to any one of the preceding claims further comprising the simultaneous or sequential administration of at least one other therapeutic agent.
9. A method according to claim 8 wherein the other therapeutic agent is a chemotherapeutic agent or a hormone.
10. A method according to claim 9 wherein the chemotherapeutic agent is selected from cyclophosphamide, vincristine, methotrexate, cisplatin, melphalan and adriamycin.

- 60 -

11. A method according to claim 9 wherein the hormone is tamoxifen or other anti-estrogens.
12. A method according to claim 1 wherein the cytokine is administered in an amount from about 0.5 μ g to about 2 mg per kilogram of body weight of mammal.
13. A method according to claim 1 wherein the mammal is a human.
14. A pharmaceutical composition effective in ameliorating the effects of breast cancer or delaying onset of breast cancer in a mammal comprising at least one cytokine or a functional derivative or agonist thereof and one or more pharmaceutically acceptable carriers and/or diluents.
15. A pharmaceutical composition according to claim 14 comprising a cytokine selected from IL-6, OSM, IL-11, LIF and EGF or other members of the EGF family.
16. A pharmaceutical composition according to claim 14 where the cytokine is OSM.
17. A pharmaceutical composition according to claim 14 wherein the cytokine is LIF.
18. A pharmaceutical composition according to claim 14 or 15 or 16 further comprising a chemotherapeutic agent or a hormone.
19. A pharmaceutical composition according to claim 18 wherein the chemotherapeutic agent is selected from cyclophosphamide, vincristine, methotrexate, cisplatin, melphalan and adriamycin.
20. A pharmaceutical composition according to claim 18 wherein the hormone is tamoxifen or other anti-estrogens.
21. Use of a cytokine or a functional derivative or agonist thereof in the manufacture of a medicament for the treatment or prophylaxis of breast cancer in a mammal.

- 61 -

22. Use according to claim 21 wherein the cytokine is IL-6, OSM, EGF, IL-11 or LIF.
23. Use according to claim 22 where the cytokine is OSM.
24. Use according to claim 22 wherein the cytokine is LIF.
25. Use according to claim 22 wherein the mammal is a human.
26. An agent comprising a cytokine or a functional derivative or agonist thereof for the treatment or prophylaxis of breast cancer in a mammal.
27. An agent according to claim 26 wherein the cytokine is IL-6, OSM, IL-11, LIF or EGF or other members of the EGF family.
28. An agent according to claim 26 wherein the cytokine is OSM
29. An agent according to claim 26 wherein the cytokine is LIF.

1/18




Fig. 1

2/18

MCF 7M IN LIQUID CULTURE




Fig. 2A

MCF 7M IN LIQUID CULTURE




Fig. 2B

3/18




Fig. 2C




Fig. 3

4/18




Fig.4

5/18

BT549 IN LIQUID CULTURE FOR 10 DAYS




Fig. 5A

BT549 IN LIQUID CULTURE FOR 10 DAYS




Fig. 5B

6/18

PRIMARY NORMAL BREAST CELLS IN LIQUID CULTURE




Fig. 6

7/18

INHIBITION OF PROLIFERATION OF MCF-7 CELLS BY ONCOSTATIN M




Fig. 7




Fig. 8

8/18

OSM INHIBITS MCF-7 CELLS IN SERUM FREE CULTURE





Fig. 9A

OSM INHIBITS MCF-7 CELLS IN SERUM FREE CULTURE



N=2

Fig. 9B

9/18

DECREASED S PHASE FRACTION OF MCF-7 CELLS EXPOSED TO OSM




Fig. 10

10/18




Fig. 11A




Fig. 11B



Fig. 11C




Fig. 11D

11/18




Fig. 12




Fig. 13A




Fig. 13B




Fig. 13C




Fig. 13D

13/18




Fig. 14




Fig. 15A



Fig. 15B




Fig. 15C




Fig. 15D

15/18




Fig. 16




Fig. 17

16/18




Fig. 18




Fig. 19

17/18




Fig. 20A




Fig. 20B

18/18




Fig. 21

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : A61K 38/19, 38/20																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) A61K and keywords as set out below																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU IPC as above																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent, Japio, Chemical Abstracts: (oncostatin)M, OSM, interleukin-6, IL-6, interleukin-11, IL-11, leukemia inhibitory factor, LIF, epidermal growth factor, EGF) and (breast, mammary) and (cancer, neoplas:)																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	US 5428012, A (SHOYAB et al) 27 June 1995 See entire document	1-29																				
X	AU 32516/93, A (AMRAD CORPORATION LIMITED) 8 July 1993 See entire document	1-29																				
P, X	AU 41871/96, A (ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.) 20 June 1996 See entire document	1-29																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier document but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 2 December 1996		Date of mailing of the international search report 20 DEC 1996																				
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (06) 285 3929		Authorized officer R.L. POOLEY Telephone No.: (06) 283 2242																				

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5216128, A, (NOVICK) 1 June 1993 See entire document	1-29
X	JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, Vol 5, no. 4, (1991), Chen, L. et al. "IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells" pages 125-136 See entire document	1-29
X	NICOLA, N.A. Ed "Guidebook to cytokines and their receptors" (1994), Sambrook and Tooze Publication at Oxford University Press See the following chapters: (i) Rose, T.M. & Bruce, A.G. "Oncostatin M (OSM)" pages 127-129 (ii) Narazaki, M. & Kishimoto, T. "Interleukin-6 (IL-6)" pages 56-58 (iii) Clark, S.C. "Interleukin-11 (IL-11)" pages 86-88 (iv) Hilton, D.J., "Leukemia Inhibitory Factor (LIF)" pages 124-126 (v) Soler, C. & Carpenter, G. "The Epidermal Growth Factor Family (EGF)" pages 194-197	14-29

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No.
PCT/AU 96/00676

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
US	5428012	AU	66608/86	AU	67765/90	DE	3643428
		DE	3645095	FR	2597108	GB	8629997
		GB	2185485	JP	62236498	ZA	8609590
		US	5120535	US	5451506	AU	15391/88
		AU	15598/88	CA	1338011	EP	290012
		EP	290948	JP	1034281	JP	1063395
		AU	14924/88	CA	1335357	DE	3853842
		EP	281363	EP	314184	JP	1503513
		JP	4502851	WO	8806628	WO	8903886
		US	5248666	AU	42354/85	DE	3587863
		EP	176588	JP	61501708	JP	2042985
		JP	2072896	JP	6032631	US	4590003
		WO	8504397	US	4645828	US	4737580
		EP	176588	JP	8016063		
AU	32516/93	CA	2104576	JP	7502514	WO	9312806
AU	41871/96	WO	9618648	EP	745094	CA	2177838
US	5216128	DE	69028671	EP	413908	JP	3157400
		US	5216128				

END OF ANNEX